0000000000061697

AUTHOR

Roland Hardt

showing 8 related works from this author

Vorgehen bei Multimorbidität

2019

Wir werden zwar immer gesunder alter, jedoch beginnt im achten Lebensjahrzehnt das Alter seine Durchschlagskraft als Risikofaktor zu entfalten. Jenseits des 80. Lebensjahres gelten Menschen nach der Definition der Europaischen Geriater aus dem Jahr 2008 als so vulnerabel, dass sie in die Kompetenz der Altersmedizin (Geriatrie) fallen. Haufig leiden die Menschen bereits an mehreren Erkrankungen gleichzeitig oder haben eine Kaskade risikobehafteter Erkrankungen mit den entsprechenden Folgeerkrankungen bereits durchlaufen. Dies ware z. B. die Arteriosklerose (Verengung und Steifigkeit der Arterien) mit Bluthochdruck und erhohten Blutfetten, die bereits zu einer manifesten Herzkranzgefaserkrank…

researchProduct

Nachuntersuchung 90 Tage nach Schlaganfall und transitorisch ischämischer Attacke im Qualitätssicherungsprojekt Rheinland-Pfalz

2018

Zusammenfassung Hintergrund In Deutschland liefern Qualitätssicherungsprojekte zahlreiche Informationen zum akuten Schlaganfall, Daten aus Nachuntersuchungen liegen hingegen kaum vor. Ziel des Nachuntersuchungsprojekts war die Erhebung von Daten zu Lebenssituation, Rezidivereignissen, Medikation und Risikofaktoreneinstellung 3 Monate nach Schlaganfall oder TIA. Material und Methoden Im zweiten Halbjahr 2012 wurden alle im Qualitätssicherungsprojekt „Akuter Schlaganfall“ in Rheinland-Pfalz erfassten Patienten zu einer Nachuntersuchung nach 90 Tagen mittels eines Fragebogens eingeladen. Ergebnisse Von 8153 Patienten nahmen 3214 (39,4 %) an der Nachuntersuchung teil (Tod im Krankenhaus: n = 37…

03 medical and health sciences0302 clinical medicineNeurology (clinical)030204 cardiovascular system & hematology030217 neurology & neurosurgeryAktuelle Neurologie
researchProduct

Prävention im Alter – Was ist gesichert?

2019

Herz- und Kreislauferkrankungen sind die haufigsten Todesursachen in Deutschland. Da das Alter fur die meisten Herz- und Kreislauferkrankungen ein eigenstandiger und unabhangiger Risikofaktor ist, sind alte Menschen hiervon besonders betroffen, wobei das Risiko mit steigendem Lebensalter sogar exponentiell ansteigt. Dies gilt v. a. fur den Bluthochdruck, der wiederum der wichtigste Risikofaktor fur die koronare Herzkrankheit (KHK; Herzkranzgefaserkrankung), die Herzinsuffizienz (Herzschwache) sowie den Schlaganfall ist. Ein weiterer Risikofaktor ist der Diabetes mellitus, der insbesondere das Risiko fur die Entwicklung einer Herzinsuffizienz erhoht, aber auch fur die anderen genannten Krank…

researchProduct

Management of Oral Anti-Coagulation in Patients with Heart Failure-Insights from the ThrombEVAL Study

2018

AbstractPatients with heart failure (HF) are frequently anti-coagulated with vitamin K-antagonists (VKAs). The use of long-acting VKA may be preferable for HF patients due to higher stability of plasma concentrations. However, evidence on phenprocoumon-based oral anti-coagulation (OAC) therapy in HF is scarce. The aim of this study was to assess the impact of the presence of HF on quality of phenprocoumon-based OAC and the subsequent clinical outcome. Quality of OAC therapy and the incidence of adverse events were analysed in a cohort of regular care (n = 2,011) from the multi-centre thrombEVAL study program (NCT01809015) stratified by the presence of HF. To assess the modifiability of outc…

MaleAdministration Oralheart failureclinical outcomeED AMERICAN-COLLEGE030204 cardiovascular system & hematologyTHERAPY ANTITHROMBOTIC THERAPYCohort StudiesPhenprocoumon0302 clinical medicinequality of careGermanyProspective Studies030212 general & internal medicineProspective cohort studyAged 80 and overOUTCOMESIncidenceHazard ratioHematologyTreatment OutcomeCohortFemaleCLINICAL-PRACTICE GUIDELINESSINUS RHYTHMmedicine.drugCohort studyRiskmedicine.medical_specialtyDrug-Related Side Effects and Adverse ReactionsHemorrhageWARFARINEJECTION FRACTION03 medical and health sciencesInternal medicinemedicineHumansAdverse effectAgedbusiness.industryWarfarinhealth care modelAnticoagulantsmedicine.diseaseoral anti-coagulationHeart failureATRIAL-FIBRILLATIONPhenprocoumonADVERSE EVENTSbusinessANTICOAGULANT-THERAPY
researchProduct

e-Health-based management of patients receiving oral anticoagulation therapy: results from the observational thrombEVAL study

2017

Essentials e-Health based health care by an expert centre may advance management of oral anticoagulation. Outcome of patients was compared between an e-health based coagulation service and regular care. Patients in the coagulation service cohort experienced a significantly better clinical outcome. Lower risk for adverse events was related to anticoagulation-specific and non-specific outcome. SummaryBackground Management of oral anticoagulation (OAC) therapy is essential to minimize adverse events in patients receiving vitamin K-antagonists (VKAs). Data on the effect of e-health-based anticoagulation management systems on the clinical outcome of OAC patients are limited. Objectives To compar…

MalePediatricsVitamin KAdministration OralComorbidity030204 cardiovascular system & hematologyRate ratioSERVICE0302 clinical medicineRisk FactorsGermanyUSUAL MEDICAL-CAREClinical endpointProspective Studies030212 general & internal medicineAged 80 and overOUTCOMESHazard ratioDABIGATRANHematologyMiddle AgedHospitalizationTreatment OutcomeCohortdelivery of healthcareFemaleepidemiologyPatient SafetytelemedicineCohort studymedicine.drugmedicine.medical_specialtyanticoagulantsHemorrhageLower riskpatient outcome assessmentWARFARIN03 medical and health sciencesThromboembolismmedicineNONVALVULAR ATRIAL-FIBRILLATIONHumansQUALITYInternational Normalized RatioAdverse effectBlood CoagulationMETAANALYSISAgedProportional Hazards ModelsRivaroxabanbusiness.industrySTROKE PREVENTIONRIVAROXABANbusinessFollow-Up Studies
researchProduct

Einführung – Charakteristik des Alters und Demografie

2019

Alter ist zunachst einmal ganz wertfrei eine chronologische Angabe. Nicht selten werden Personen oder Gegenstande bereits bei ihrer Nennung, z. B. durch Angabe ihres Entstehungsjahrgangs mit einer Altersangabe konnotiert. Auch dies mag zunachst neutral erscheinen, erhalt jedoch relativ rasch durch begleitende Attribute einen wertenden Charakter. Dies kann sowohl eine negative Charakterisierung, z. B. veraltet bedeuten, aber auch durchaus positive Konnotationen durch Begriffe wie gereift oder klassisch enthalten.

researchProduct

Subtherapeutic Anticoagulation Control under Treatment with Vitamin K-Antagonists—Data from a Specialized Coagulation Service

2019

AbstractIn contrast to overanticoagulation, evidence on risk factors and outcome of subtherapeutic oral anticoagulation (OAC) with vitamin K-antagonists (VKAs) under optimum care is limited. We investigated the clinical phenotype, anticoagulation control, and clinical outcome of 760 VKA patients who received OAC therapy by a specialized coagulation service in the thrombEVAL study (NCT01809015). During 281,934 treatment days, 278 patients experience ≥ 1 episode of subtherapeutic anticoagulation control and had lower quality of OAC therapy compared to 482 patients without subtherapeutic international normalized ratio: 67.6%, interquartile range (IQR) 54.9%/76.8% versus 81.0%, IQR 68.5%/90.4%;…

MaleQuality Control0301 basic medicineVitaminmedicine.medical_specialtyVitamin KAdministration OralComorbidity030204 cardiovascular system & hematologyVitamin k03 medical and health scienceschemistry.chemical_compound0302 clinical medicineFibrinolytic AgentsRecurrenceRisk FactorsInterquartile rangeInternal medicineAtrial FibrillationmedicineHumansThrombolytic TherapyInternational Normalized RatioBlood CoagulationStrokeAgedProportional Hazards ModelsAged 80 and overbusiness.industryProportional hazards modelCase-control studyAnticoagulantsHematologyMiddle Agedmedicine.diseaseComorbidityPhenotypeTreatment Outcome030104 developmental biologyCoagulationchemistryCase-Control StudiesFemalebusinessFollow-Up StudiesThrombosis and Haemostasis
researchProduct

Relevance of Polypharmacy for Clinical Outcome in Patients Receiving Vitamin K Antagonists.

2018

BACKGROUND Although polypharmacy is associated with a negative clinical outcome in various settings and commonly observed in patients receiving oral anticoagulation therapy, evidence on the relevance for the clinical outcome of anticoagulated patients is currently limited. The aim of the study was to investigate the effect of polypharmacy on the clinical outcomes among patients taking phenprocoumon. DESIGN Prospective cohort study. SETTING Regular medical care. PARTICIPANTS Information on 2011 individuals receiving vitamin K antagonists was available for analysis from the prospective multicenter thrombEVAL study. MEASUREMENTS Data were obtained from clinical visits, computer-assisted interv…

Malemedicine.medical_specialtyVitamin KAdministration OralHemorrhage030204 cardiovascular system & hematologyPhenprocoumonCohort Studies03 medical and health sciences0302 clinical medicineRisk FactorsInternal medicineGermanyPrevalenceMedicineHumansCumulative incidenceDrug Interactions030212 general & internal medicineInternational Normalized RatioMultiple Chronic ConditionsProspective StudiesRisk factorMortalityProspective cohort studyAdverse effectAgedPolypharmacybusiness.industryMedical recordHazard ratioAnticoagulantsHospitalizationPolypharmacyFemaleGeriatrics and GerontologyDrug Monitoringbusinessmedicine.drugJournal of the American Geriatrics Society
researchProduct